Thymosin Beta-4 (TB-4) is a naturally occurring 43-amino-acid peptide found in many cells and tissues that may support cell migration, tissue remodeling, and cell survival. Other potential benefits include regulating inflammatory responses, supporting angiogenesis and tissue regeneration, and contributing to wound healing, skin and dermal repair, and corneal and ocular tissue recovery.
Many of these potential benefits may be connected to how TB-4 works at the cellular level. TB-4 binds G-actin and can help regulate the cell’s internal structure, which may allow cells to change shape and move toward damaged tissue. Alongside actin regulation, TB-4 may influence signaling pathways involved in cell survival, migration, and new blood vessel formation. These mechanisms have also led researchers to investigate TB-4 in cardiovascular and neurological tissue repair, although these areas remain largely experimental. Evidence currently ranges from laboratory and animal studies to a smaller number of human trials. As a result, TB-4 shows potential across several repair-related processes, but stronger human research is still needed to establish its clinical benefits. Investigational forms, including RGN-259 and recombinant human thymosin beta-4, have also been evaluated in human clinical trials for specific applications.
10 Potential Benefits of Thymosin Beta 4 are:
- Cell Migration and Tissue Remodeling
- Inflammatory Response Modulation
- Cell Protection and Survival
- Angiogenesis and Blood Vessel Formation
- Tissue Repair and Regeneration
- Wound Healing
- Skin and Dermal Repair
- Corneal and Ocular Tissue Healing
- Cardiovascular Tissue Repair
- Neurological Tissue Repair
- Cell Migration and Tissue Remodeling
Thymosin Beta-4 (TB-4) may support cell migration by acting as a major actin-sequestering molecule. TB-4 binds G-actin and influences actin polymerization, F-actin formation, cytoskeletal reorganization, and proteins such as zyxin. These processes may support the movement of repair-related cells, including keratinocytes, endothelial cells, and stem or progenitor cells, toward damaged tissue.
Tissue remodeling involves a different repair process. TB-4 has been studied for potential effects on collagen deposition, extracellular matrix (ECM) organization and adhesion, myofibroblast activity, fibrosis, and structural restoration after injury. A 2026 scoping review of 80 studies reported that 10 studies (12.5%) examined cell migration and 4 (5%) examined collagen or ECM remodeling (McGuire et al., 2026). Evidence remains largely preclinical and does not establish these effects as clinical benefits in humans.
- Inflammatory Response Modulation
When tissue is injured, immune cells release inflammatory mediators that help coordinate the body’s response to damage. TB-4 may help regulate this activity by influencing macrophage behavior and inflammatory signaling, which could support the controlled resolution of inflammation rather than prolonged inflammatory activity.
A 2025 mouse and cell study found that TB-4 reduced pro-inflammatory M1 macrophage markers, including TNF-α, IL-1β, and iNOS, while increasing M2-associated markers such as ARG1 and IL-10 (Zhu et al., 2025). These changes suggest TB-4 may promote M2 macrophage polarization, which is associated with inflammation resolution and tissue repair. However, these findings are mainly preclinical, so the extent of TB-4’s anti-inflammatory effects in humans remains uncertain.
- Cell Protection and Survival
For cells affected by injury or stress, TB-4 may offer potential therapeutic benefits by helping cells stay alive and functional. TB-4 may support cell viability and influence apoptosis, the natural process of programmed cell death. By regulating this process, TB-4 could reduce the loss of cells that can still survive after injury.
Preclinical research supports this potential cell-protective effect. In a 2022 study of human corneal stromal cells, ethanol injury increased apoptosis to 8.75 times the control level, while TB-4 treatment significantly reduced apoptosis (Liu et al., 2022). These findings suggest that TB-4 may help protect stressed cells from excessive cell death and support cell survival, although evidence for these effects in humans remains limited.
- Angiogenesis and Blood Vessel Formation
As damaged tissue needs oxygen and nutrients, TB-4 may support angiogenesis by helping endothelial cells move and form new blood vessels. TB-4 can also support capillary formation and neovascularization, which could improve blood flow around the injured tissue.
Research has linked these effects to VEGF-related signaling and pathways involving PI3K/AKT/mTOR and HIF-1α, which regulate vascular responses to ischemia and tissue injury. In a 2025 animal study of diabetic wounds, Tβ4-enriched exosomes increased blood flow and levels of CD31, a marker of cells that line blood vessels, and α-SMA, a marker linked to blood vessel support and stability, by day 14 (Yu et al., 2025). The results suggest that TB-4 may benefit blood vessel growth and blood supply, but the study tested a Tβ4-exosome treatment in animals rather than TB-4 alone in humans.
- Tissue Repair and Regeneration
TB-4 may contribute to a broader regenerative cascade involving stem/progenitor cell recruitment, differentiation, extracellular matrix activity, angiogenesis, neurogenesis, and tissue-specific repair. These processes may help damaged tissue recruit mesenchymal stem cells and other progenitor cells and direct them toward functions involved in structural restoration, including osteogenesis and bone regeneration.
A 2025 preclinical study evaluated a complex platform combining a Tβ4-modified hyaluronic-acid hydrogel with BMSC-derived exosomes. The platform promoted stem-cell homing, angiogenesis, neurogenesis, osteogenic differentiation, and new bone formation (Xi et al., 2025). These findings indicate potential regenerative activity, but they reflect a multi-component experimental delivery system rather than standalone TB-4 treatment in humans.
- Wound Healing
TB-4 may support several experimental wound-healing processes, including keratinocyte and endothelial-cell migration, re-epithelialization, collagen deposition, granulation tissue formation, angiogenesis, and wound contraction. Together, these processes contribute to wound closure and restoration of the damaged tissue barrier. TB-4 has also been investigated in human studies involving chronic wounds, including pressure ulcers and venous stasis ulcers, although clinical evidence remains limited.
In a 2026 preclinical study, a Tβ4-loaded microneedle treatment achieved about 95.7% wound healing by day 10 and reduced the remaining wound gap by roughly 59% compared with untreated controls (He et al., 2026). While these findings indicate potential effects on epithelial repair, inflammation, and wound closure, they came from an experimental delivery system rather than standalone TB-4 treatment in humans.
- Skin and Dermal Repair
When skin becomes damaged, TB-4 could support dermal repair by helping keratinocytes move across the affected area and rebuild the epidermis, the outer layer of the skin. This activity could support epidermal recovery and help restore the skin barrier, while dermal remodeling may help reorganize the deeper structure of damaged skin.
Earlier clinical research also supports TB-4’s potential role in skin and dermal repair. In a Phase 2 study of 73 patients with venous stasis ulcers, topical TB-4 showed the strongest healing signal at the 0.03% dose, while about 25% of patients achieved complete wound healing within 3 months (Guarnera et al., 2010). Although this is older evidence, it provides human clinical data supporting TB-4’s potential role in skin and dermal repair.
- Corneal and Ocular Tissue Healing
TB-4 may support corneal re-epithelialization by promoting epithelial-cell migration and restoration of the corneal epithelial barrier. RGN-259, an investigational TB-4 ophthalmic formulation, has been studied for persistent corneal epithelial defects, neurotrophic keratopathy, and dry eye disease, using measures such as corneal fluorescein staining and epithelial healing.
In a Phase III study, 60% of patients receiving 0.1% TB-4 ophthalmic solution achieved complete corneal epithelial healing within four weeks, compared with 12.5% receiving placebo (Sosne et al., 2023). While this result supports further investigation, the study involved a small patient population and requires confirmation in larger clinical studies. TB-4 has received FDA orphan-drug designation for neurotrophic keratopathy, but orphan designation does not constitute FDA approval.
- Cardiovascular Tissue Repair
Following ischemic damage, heart tissue receives less oxygen because blood flow is reduced or blocked. TB-4 could have potential benefits during this period by helping protect cardiomyocytes, the muscle cells responsible for heart contraction, and supporting their survival. Preserving these cells may limit the amount of functional cardiac tissue lost after injury.
Beyond protecting existing heart cells, TB-4 has the potential to support the repair environment around damaged myocardium. Recent experimental research provides support for this potential protective role. In a 2025 preclinical study, recombinant TB-4 reduced cardiomyocyte apoptosis, limited infarct size, and improved cardiac function in mouse models of ischemia and myocardial infarction (Zhang et al., 2025). Together, these effects suggest a possible role for TB-4 in protecting damaged cardiac tissue and supporting heart repair, although this potential has not yet been established as a clinical benefit in humans.
- Neurological Tissue Repair
TB-4 may have potential benefits for neurological tissue repair by helping protect neurons and other neural cells from damage after injury. By supporting cell survival, TB-4 could help preserve more functioning neural tissue, which may provide a stronger foundation for recovery and reduce the loss of cells needed for normal neurological activity.
Recovery also depends on how damaged neural tissue responds after the initial injury. TB-4 may influence neurogenesis, the formation of new nerve cells, while supporting neuronal recovery and repair-related cellular activity. These combined actions could help maintain neural tissue structure and support the rebuilding of damaged areas, although TB-4 remains investigational for neurological repair in humans.
How Does TB-4 Work?
TB-4 works mainly by binding to and sequestering G-actin, the free form of actin that cells use to build and reorganize their internal structure. By temporarily holding G-actin and regulating how much is available to form F-actin, TB-4 may help control cytoskeletal remodeling. This allows cells to change shape and move toward damaged areas, where they can take part in tissue repair and support other repair-related cells.
As cells respond to damage, TB-4 may also influence signaling pathways such as ILK/Akt and PI3K/Akt/eNOS. These pathways are involved in cell survival, migration, and new blood vessel formation, linking TB-4’s actin-related activity with broader repair processes. TB-4 can also be enzymatically broken down to produce Ac-SDKP, a small peptide associated with reduced inflammation and fibrosis. Through these connected mechanisms, TB-4 may influence cell movement, survival, angiogenesis, inflammation control, scar formation, and tissue remodeling.
What Does Research Say About TB-4 Benefits?
Research on TB-4 ranges from cell studies and animal models to a smaller number of human clinical trials. Cell-based research has helped explain how TB-4 may influence actin regulation, cell migration, survival, inflammation, and blood vessel formation, while animal studies have tested these effects in damaged skin, corneal tissue, cardiac tissue, and other injury models. These experimental findings support several possible benefits, but they do not confirm that the same effects will occur in people.
- A 2026 scoping review identified 80 studies evaluating TB-4, TB-500, or related derivatives in tissue healing and regeneration. The authors concluded that the evidence remains largely preclinical, with human research concentrated mainly in ocular and wound-healing applications (McGuire et al., 2026).
- In a Phase III trial, 6 of 10 patients (60%) treated with 0.1% RGN-259, a TB-4 ophthalmic solution, achieved complete corneal epithelial healing after 4 weeks, compared with 1 of 8 patients (12.5%) receiving placebo (Sosne et al., 2022).
- In a 2025 randomized trial of 96 STEMI patients, a post hoc subgroup receiving 1 μg/kg recombinant TB-4 within 8 hours after PCI had an infarcted myocardial area of 24.86% ± 2.79%, compared with 34.73% ± 2.79% with placebo at 90 days (Zhang et al., 2025). The overall trial did not show a significant infarct-area difference, so this subgroup result requires caution.
- In a preclinical cardiomyocyte study, TB-4 pretreatment reduced TUNEL-positive apoptotic cells to 4.4% ± 2.2% during oxidative stress, supporting a potential anti-apoptotic effect through proteins such as Bcl-2 (Wei et al., 2012).
- Recent research found that recombinant TB-4 significantly reduced cardiomyocyte apoptosis and improved cardiac function in mouse ischemia-reperfusion models through ErbB2/Raf1 signaling, while also reducing infarct size in myocardial-infarction models (Zhang et al., 2025).
Overall, current research suggests that TB-4 may have promising roles in cell survival, wound healing, corneal repair, angiogenesis, and tissue regeneration, but the evidence remains largely preclinical, and more human clinical studies are needed to confirm these benefits.
How Is Thymosin Beta 4 (TB4) Different From TB-500?
TB-4 is a naturally occurring 43-amino-acid peptide that may help regulate actin dynamics, cell movement, and repair-related activity, whereas TB-500 is generally described as a synthetic fragment or analog derived from TB-4. Research-grade TB-4 may have broader research support across cell, animal, and human studies, while research specifically focused on TB-500 appears more limited. Do not treat the two terms as interchangeable, as TB-500 terminology and peptide composition can vary across research and commercial sources.
| Comparison Point | TB-4 | TB-500 |
| Origin | Endogenous peptide found in mammalian cells and tissues | Synthetic TB-4-derived peptide |
| Peptide Structure | Full-length thymosin beta-4 | N-terminal acetylated fragment 17-23, Ac-LKKTETQ |
| Amino-Acid Length | 43 amino acids | 7 amino acids |
| Actin-Related Region | Contains the LKKTET actin-binding region within the full peptide | Contains the TB-4-derived LKKTETQ sequence |
| Research Base | Studied in cell models, animals, and human clinical research | Research specifically involving TB-500 is much more limited |
| Human Evidence | Human studies exist for specific TB-4 formulations and indications | FDA reported identifying no human exposure data for TB-500 fragment products in its 2026 review |
| Natural Presence | Naturally occurring in the body | Synthetic |
| Terminology | Refers to full-length thymosin beta-4 | Commercial naming can be ambiguous and may be used incorrectly for TB-4 |
| Interchangeable? | No | No. TB-500 should not automatically be treated as full-length TB-4 |
What Are the Potential Side Effects of Thymosin Beta 4?
Potential side effects associated with TB-4 may include injection-site reactions, lethargy or fatigue, headaches or dizziness, and mild nausea. These effects may vary between individuals, and the available human safety data are still limited, making the full side-effect profile of TB-4 uncertain.
4 common side effects of thymosin beta 4 are:
- Injection Site Reactions
TB-4 may be associated with localized reactions after injectable administration, such as bruising or irritation around the injection area. However, redness, pain, swelling, and similar reactions should not be attributed directly to TB-4 unless they are specifically reported with the formulation studied, as some reactions may result from the injection procedure itself. Attribute such events to TB-4 only when supported by formulation-specific clinical safety data and causality assessment.
- Lethargy and Fatigue
When considering potential TB-4 side effects, fatigue or lethargy may be reported as feelings of tiredness, low energy, or reduced activity. Their direct relationship to TB-4 remains uncertain because current clinical evidence does not clearly establish them as treatment-related effects. Fatigue and lethargy are not established side effects of TB-4 based on current human evidence. If these symptoms occur during a clinical study, they should be reported as adverse events unless investigators establish a treatment-related association.
- Headaches and Dizziness
Some individuals can experience headaches or dizziness while using TB-4, which may involve head pain, lightheadedness, or a temporary feeling of imbalance. The severity and duration of these symptoms can vary between individuals. Headache and dizziness are not established universal side effects of TB-4 based on current evidence. If these symptoms are reported during a clinical study, they should be described as adverse events rather than effects caused by TB-4 unless causality is established.
- Mild Nausea
Mild nausea may occur during TB-4 use, causing temporary stomach discomfort or an unsettled feeling. It is not considered a universal side effect. Its frequency and severity may depend on the TB-4 formulation studied.Adverse events need to be evaluated within specific clinical studies because full-length TB-4, recombinant human TB-4 (rhTB4), RGN-259, topical formulations, intravenous formulations, and TB-500 represent different exposures.
